187 related articles for article (PubMed ID: 34980800)
1. Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone.
Okahashi N; Kubo M; Hoshino E; Uchihara M; Amano I; Tanaka H
Intern Med; 2022 Jul; 61(14):2209-2213. PubMed ID: 34980800
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
[TBL] [Abstract][Full Text] [Related]
3. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
Lim SK; Bee PC; Keng TC; Chong YB
Clin Nephrol; 2013 Sep; 80(3):227-30. PubMed ID: 23298519
[TBL] [Abstract][Full Text] [Related]
4. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
[TBL] [Abstract][Full Text] [Related]
5. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
[TBL] [Abstract][Full Text] [Related]
6. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
7. Pure red-cell aplasia induced by anti-erythropoietin antibodies in peritoneal dialysis.
Coronel F; García-Mena M; Martínez R
Clin Nephrol; 2004 Feb; 61(2):155-8. PubMed ID: 14989637
[TBL] [Abstract][Full Text] [Related]
8. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.
Lee H; Yang J; Kim H; Kwon JW; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S
J Korean Med Sci; 2010 Nov; 25(11):1676-9. PubMed ID: 21060762
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML
Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778
[TBL] [Abstract][Full Text] [Related]
10. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.
Katagiri D; Shibata M; Katsuki T; Masumoto S; Katsuma A; Minami E; Hoshino T; Inoue T; Tada M; Hinoshita F
Clin Exp Nephrol; 2010 Oct; 14(5):501-5. PubMed ID: 20652821
[TBL] [Abstract][Full Text] [Related]
11. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
Macdougall IC
Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
[TBL] [Abstract][Full Text] [Related]
12. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
Casadevall N
Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii37-41. PubMed ID: 14608000
[TBL] [Abstract][Full Text] [Related]
13. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.
Hashimoto K; Harada M; Kamijo Y
Int J Hematol; 2016 Oct; 104(4):502-5. PubMed ID: 27338269
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
Wu G; Wadgymar A; Wong G; Ting R; Nathoo B; Mendelssohn D; Pandeya S; Sapir D; Tam P
Am J Kidney Dis; 2004 Aug; 44(2):264-9. PubMed ID: 15264184
[TBL] [Abstract][Full Text] [Related]
15. Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia.
Weeraratne DK; Kuck AJ; Chirmule N; Mytych DT
Clin Vaccine Immunol; 2013 Jan; 20(1):46-51. PubMed ID: 23114696
[TBL] [Abstract][Full Text] [Related]
16. [Early onset of anti- erythropoietin antibody-mediated pure red cell aplasia after commencement of subcutaneous administration of epoetin-β].
Tanaka A; Tsukada J; Morimoto H; Katsuragi T; Nakanishi T; Watanabe S; Hirase N; Motomura S
Rinsho Ketsueki; 2012 Jan; 53(1):110-2. PubMed ID: 22374534
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin-induced, antibody-mediated pure red cell aplasia.
Rossert J;
Eur J Clin Invest; 2005 Dec; 35 Suppl 3():95-9. PubMed ID: 16281965
[TBL] [Abstract][Full Text] [Related]
18. Pure red-cell aplasia and epoetin therapy.
Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
[TBL] [Abstract][Full Text] [Related]
19. Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
Macdougall IC
Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii18-21. PubMed ID: 16079325
[TBL] [Abstract][Full Text] [Related]
20. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
[No Abstract] [Full Text] [Related]
[Next] [New Search]
